Healthcare Biz Review: Vivus’ Second TRY, Intuitive Surgical’s PROSPECTS
Drug maker Zogenix (NASDAQ:ZGNX) shares move way up, subsequent to word that the FDA had accepted for review its lead investigational product candidate for the treatment of chronic pain. The typical completion of a standard review of a new drug application is 10 months from submission, and accordingly the agency has assigned a target action date of March 1, 2013 for the Zohydro ER application.
Don’t Miss: Will Vivus Share Arena’s VICTORY?
Shares of Vivus (NASDAQ:VVUS) moved up Monday in anticipation that the FDA will approve its diet drug Qnexa by late Tuesday. This is the second attempt for the med, and if okayed will be the second weight loss treatment to be approved by the agency in the past two months.
Intuitive Surgical (NASDAQ:ISRG) shares should be purchased with any pullback, says William Blair, following the drop last week on Mako Surgical’s (NASDAQ:MAKO) negative preannouncement. The analyst (Outperform) says that its channel checks foresee strong demand for both systems and procedures, and second quarter procedure growth is expected to reach the high end of guidance.
Don’t Miss: Bulls CHARGE into This Earnings Season.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.